Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2019 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Friday, Oct. 4,...
September 05, 2019 16:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79,...
September 03, 2019 16:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
August 30, 2019 18:05 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 30, 2019,...
August 19, 2019 17:48 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application

CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced it had received a Complete...
August 08, 2019 15:27 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS)

CAMBRIDGE, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, was informed earlier today that an adverse...
August 07, 2019 16:05 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the...
July 31, 2019 18:04 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2019, that...
July 31, 2019 16:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Announce Second Quarter 2019 Financial Results and Recent Corporate Developments on August 7, 2019

CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2019 financial...
June 28, 2019 18:05 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2019, that...